Clinical trial
A Phase I-IIa, Open Label, Multi-Center, Dose Escalating Study to Evaluate the Safety of Intravenous Pegylated Liposomal Dexamethasone Sodium Phosphate (Oncocort) as Monotherapy in Patients With Previously Treated Progressive Multiple Myeloma
NCT03033316 is registered in ClinicalTrials.gov with Enceladus Pharmaceuticals BV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I-IIa, Open Label, Multi-Center, Dose Escalating Study to Evaluate the Safety of Intravenous Pegylated Liposomal Dexamethasone Sodium Phosphate (Oncocort) as Monotherapy in Patients With Previously Treated Progressive Multiple Myeloma
- Lead sponsor
- Enceladus Pharmaceuticals BV
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- January 31, 2017
- Completion date
- August 31, 2020
- Enrollment
- 7 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.